switching to retatrutide from tirzepatide Navigating the Weight Loss Maze: vs. Is retatrutide better than tirzepatide?

The consequences sit elsewhere

N Engl J Med 385(10):896907

The focus shifted to GLP-1, with Svetlana Mojsov identifying its insulin-stimulating fragment, GLP-1(7-37), in 1983

Key weight loss results at 48 weeks by group: Response rates at 48 weeks (12 mg dose): 100% achieved greater than or equal to 5% weight loss 93% achieved greater than or equal to 10% weight loss 83% achieved greater than or equal to 15% weight loss The cardiometabolic improvements were also significant, with reductions in blood pressure, triglycerides, LDL cholesterol, HbA1c, fasting glucose, and fasting insulin across all dose groups

EMA Decision P/0336/2024 Paediatric Investigation Plan for Retatrutide

References: 1